美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Ablynx NV

52.87

0.0000

成交量：- -

成交额：- -

市值：4.16亿

市盈率：-25.28

高：52.87

开：52.87

低：52.87

收：52.87

52周最高：55.29

52周最低：17.75

股本：786.16万

流通股本：786.16万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.0911

每股收益(LYR):-2.0911

净资产收益率：--

总资产收益率：--

市净率：2.01

市盈率(LYR):-25.28

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Ablynx NV

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.ablynx.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Ablynx Nv于2001年7月4日在比利时法律下成立为有限责任公司（naamloze vennootschap）。该公司是一家后期临床生物制药公司，利用其专有的纳米抗体平台开发广泛的未满足的医疗需求的治疗适应症。该公司认为，纳米抗体是下一代蛋白质治疗技术的领先者。该公司拥有超过45种专有和合作的纳米抗体计划，包括血液学，炎症，传染病，自身免疫性疾病，肿瘤学和免疫肿瘤学。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ABLX/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ABLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABLX\",,,,,undefined,":{"symbol":"ABLX","market":"US","secType":"STK","nameCN":"Ablynx NV","latestPrice":52.87,"timestamp":1529956800000,"preClose":52.87,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":7861635,"shares":7861635,"eps":-2.091075,"marketStatus":"交易中","change":0,"latestTime":"03-13 09:45:24 EDT","open":52.87,"high":52.87,"low":52.87,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.091075,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1773432000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":52.87,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABLX\",,,,,undefined,":{"symbol":"ABLX","floatShares":7861635,"roa":"--","roe":"--","lyrEps":-2.091075,"shares":7861635,"dividePrice":0,"high":52.87,"amplitude":0,"preClose":52.87,"low":52.87,"week52Low":17.75,"pbRate":"2.01","week52High":55.29,"institutionHeld":0,"latestPrice":52.87,"eps":-2.091075,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.091075,"open":52.87,"prevYearClose":52.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ABLX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ABLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ABLX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.ablynx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.0377},{"period":"3month","weight":-0.023},{"period":"6month","weight":0.0132},{"period":"1year","weight":0.1918},{"period":"ytd","weight":-0.0233}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ablynx Nv于2001年7月4日在比利时法律下成立为有限责任公司（naamloze vennootschap）。该公司是一家后期临床生物制药公司，利用其专有的纳米抗体平台开发广泛的未满足的医疗需求的治疗适应症。 该公司认为，纳米抗体是下一代蛋白质治疗技术的领先者。 该公司拥有超过45种专有和合作的纳米抗体计划，包括血液学，炎症，传染病，自身免疫性疾病，肿瘤学和免疫肿瘤学。","exchange":"NASDAQ","name":"Ablynx NV","nameEN":"Ablynx NV"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ABLX\",market:\"US\",,,undefined,":null}}